Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H1 2017

  • ID: 4311820
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • Merck & Co Inc
  • Nuevolution AB
  • Resverlogix Corp
  • MORE
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Pipeline Review, H1 2017

Summary:

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 4 and 3 respectively. Report covers products from therapy areas Oncology, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Follicular Lymphoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Lymphoma, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis and Systemic Lupus Erythematosus.

The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • Merck & Co Inc
  • Nuevolution AB
  • Resverlogix Corp
  • MORE
  1. Introduction
  2. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
  3. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
  13. F. Hoffmann-La Roche Ltd
  14. Forma Therapeutics Inc
  15. Incyte Corp
  16. Merck & Co Inc
  17. Nuevolution AB
  18. Resverlogix Corp
  19. Trillium Therapeutics Inc
  20. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
  21. birabresib - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. CPI-0610 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. FT-1101 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. INCB-54329 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. NUE-7770 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. RG-6146 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. RVX-2135 - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. TTI-281 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. ZEN-3694 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
  58. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
  59. Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
  60. Featured News & Press Releases
  61. Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
  62. Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
  63. Sep 16, 2016: Presentation of preclinical data on its BET BD1 program at Discovery on Target
  64. Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
  65. Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
  66. Mar 18, 2015: New Data Investigating Merck’s MK-8628 in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR
  67. Nov 12, 2014: Oncoethix Starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
  68. Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
  69. Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
  70. Jan 31, 2013: OncoEthix Doses First Patient In Phase I Trial Of OTX015 For Treatment Of Hematologic Malignancies
  71. Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
  72. Nov 21, 2012: Oncoethix Recevies FDA Clearance For Phase I Trial Of OTX015 In Patients With Advanced Hematologic Malignancies
  73. Nov 09, 2012: Oncoethix Reports Preclinical Activity Of OTX015 At 24th EORTX-NCI-AACR Symposium
  74. Aug 16, 2012: Researchers Develop Potential Male Contraceptive Pill
  75. Appendix
  76. Methodology
  77. Coverage
  78. Secondary Research
  79. Primary Research
  80. Expert Panel Validation
  81. Contact Us
  82. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Companies, H1
  6. Products under Development by Companies, H1
  7. Products under Development by Companies, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1 2017 (Contd..2), H1
  9. Number of Products by Stage and Mechanism of Actions, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Pipeline by F. Hoffmann-La Roche Ltd, H1
  13. Pipeline by Forma Therapeutics Inc, H1
  14. Pipeline by Incyte Corp, H1
  15. Pipeline by Merck & Co Inc, H1
  16. Pipeline by Nuevolution AB, H1
  17. Pipeline by Resverlogix Corp, H1
  18. Pipeline by Trillium Therapeutics Inc, H1
  19. Dormant Projects, H1
  20. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Incyte Corp
  • Merck & Co Inc
  • Nuevolution AB
  • Resverlogix Corp
  • Trillium Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll